CAVE CREEK, AZ - (NewMediaWire) - November 3, 2015 - Endexx Corporation (OTC PINK: EDXC), a provider of innovative medical marijuana management and proprietary technology solutions, announced today that it has entered into a collaboration agreement with Brown, Griglack, & Zambrano, a New Jersey GP, specializing in financial modeling, actuarial studies, and quantitative analysis. BGZ has been engaged to provide quantitative research and consulting services to analyze and improve new and existing products, including: the m3hub©, Autospense™, and Dudad© platforms.
Todd Davis, CEO of Endexx, stated, "The BGZ team has a distinctive set of skills that will enhance the value of Endexx's proprietary technology products. Their expertise will expedite the process of finalizing product development and conversion to client acquisition."
Mr. Zambrano of BGZ stated, "After reviewing the technology, we believe that Endexx has some truly innovative products. We are confident that we can help refine these products to reach a broader client base. We see great value in product integration and data driven analytics -- Brown, Griglack, Zambrano hopes to utilize these ideas to shape Endexx into an industry leader in technology. Our goal is to add value to Endexx products and utilize tangible ROI analysis to attract clients and investors."
Endexx is accelerating go to market strategies with our current products and new development that the company has been finalizing in 2015. Updates on technology advancement and contracts are forthcoming.
Endexx provides innovative medical marijuana management and technology solutions. Endexx, with its collaborative partners and consultants, develops and distributes two consumable product lines derived from industrial hemp, which is organic and naturally rich in phytocannabinoids. The company has two technology products and services that launched in 2014 -- the m3hub and the Autospense™. Both products provide essential solutions to promote regulatory compliance and full accountability through "seed to sale" inventory management and tracking. Based on principles developed by the pharmacological industry, the m3hub platform is the first standardized software solution for tracking pharmaceutical grade marijuana that maintains compliance with federal, state and local regulations. It is intended to provide a smooth transition to an eventual federal mandate. The Autospense™ is a high-tech marijuana inventory control and dispensing device that provides up-to-the-minute accounting details and ensures both product and patient security. By automating the dispensing process, Autospense™ increases productivity and reduces costs for marijuana retailer, while enhancing their service quality by reducing transaction time for customers. Websites include: www.cbdunlimited.com, www.cbdhealthsolutions.com, www.endexx.com, www.m3hub.com.
Safe Harbor Notice
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company's business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company's periodic filings with the Security and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.